Sign in

David Rosa

Chief Executive Officer, President, and Director at NEUROONE MEDICAL TECHNOLOGIES
Board
Since July 2017
Age
60 years
Education
Holds an MBA from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
Tenure
Joined NMTC in July 2017 as Chief Executive Officer, President, and Director, and has maintained this leadership role while overseeing the merger of NeuroOne, Inc. into NMTC in December 2019.

Also at NEUROONE MEDICAL TECHNOLOGIES

CV
Christopher Volker
Chief Operating Officer
MC
Mark Christianson
Business Development Director and Medical Sales Liaison
RM
Ronald McClurg
Chief Financial Officer

About

David Rosa has built an impressive career in the medical device industry, demonstrating a strong blend of technical, strategic, and operational leadership throughout his journey. His dedication and expertise have seen him traverse several high-level roles in prominent companies, contributing to groundbreaking advancements and capital market successes, including raising $200 million.

Prior to his current role at NMTC, he led organizations as Chief Executive Officer and President at Sunshine Heart, Inc. (now Nuwellis, Inc.) and was at the helm at Milksmart, Inc., with earlier significant contributions at St. Jude Medical, Inc. and other industry leaders.

Beyond his executive roles, his career is marked by influential board memberships and a commitment to innovation—holding multiple patents in medical devices—and building robust teams to drive growth and change across sectors.

His extensive background and leadership acumen have not only shaped the strategic initiatives at NMTC but also inspired a broader industry vision, positioning him as a key figure in advancing healthcare technologies.

$NMTC Performance Under David Rosa

Past Roles

OrganizationRoleDate RangeDetails
NeuroOne, Inc. CEO and DirectorOctober 2016 - December 2019Merged with NMTC
Sunshine Heart, Inc. (now Nuwellis, Inc.) CEO and PresidentNovember 2009 - November 2015Publicly-held early-stage medical device company
Milksmart, Inc. CEO2008 - November 2009Company specialized in medical devices for animals
St. Jude Medical, Inc. Vice President of Global Marketing2004 - 2008Focused on cardiac surgery and cardiology
C.R. Bard Inc. Senior RoleN/AInvolved in marketing, product development, and business development
Boston Scientific Inc. Senior RoleN/AResponsibilities in marketing, product development, and business development

External Roles

OrganizationRoleDate Range
Biotricity Inc. (Nasdaq: BTCY) DirectorN/A
BioRestorative Therapies, Inc. (Nasdaq: BRTX) DirectorN/A
Healthcare Triangle, Inc. (Nasdaq: HCTI) DirectorN/A

Fixed Compensation

Data from  FY 2024
Component NameAmountPayment ScheduleAdditional Details
Base Salary $521,856 Regular payroll disbursement throughout FY 2024N/A
Severance Benefits in Case of Change in Control $1,565,568 total cash payment Lump sum upon termination due to change in controlCash Payment breakdown: 2.0× base salary ($1,043,712 ) + 2.0× target bonus ($521,856 ). Also includes full vesting of equity awards and 24-month company-paid health insurance.

Performance Compensation

Data from  FY 2024

Non-Equity Incentive Plan Compensation

Metric [Unit]**Details
Target Bonus (% of Base Salary)50%, equating to $260,928
Performance MetricsResearch & development goals, financing goals, commercialization milestones, and corporate objectives
Achievement Level / Threshold85% achievement of performance targets
Actual Bonus PaymentApproximately $221,789 (85% of target bonus, i.e., 0.85 × $260,928)
Evaluation PeriodFiscal Year 2024
Vesting ScheduleN/A

Equity-Based Incentive Awards

Metric [Unit]**Details
Vesting Schedule (Stock Options)25% vest on November 9, 2024 and the remaining shares vest in equal monthly installments over the following 36 months
Vesting Schedule (Restricted Stock Units)25% vest on the first, second, third, and fourth anniversaries of February 18, 2024, beginning February 18, 2025
Grant Date Fair Value (Stock Options)$562,175
Performance Metrics / TargetsNot provided for the equity awards

Note: Detailed thresholds, caps, weights, and other specific performance conditions were not provided in the documents.